

Accepted Manuscript

Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy

Anna-Maria Szczesniak, Richard F. Porter, James T. Toguri, Joanna Borowska-Fielding, Simon Gebremeskel, Anuja Siwakoti, Brent Johnston, Christian Lehmann, Melanie E.M. Kelly

PII: S0028-3908(16)30366-5

DOI: [10.1016/j.neuropharm.2016.08.030](https://doi.org/10.1016/j.neuropharm.2016.08.030)

Reference: NP 6429

To appear in: *Neuropharmacology*


Received Date: 7 February 2016

Revised Date: 18 August 2016

Accepted Date: 24 August 2016

Please cite this article as: Szczesniak, A.-M., Porter, R.F., Toguri, J.T., Borowska-Fielding, J., Gebremeskel, S., Siwakoti, A., Johnston, B., Lehmann, C., Kelly, M.E.M., Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy, *Neuropharmacology* (2016), doi: 10.1016/j.neuropharm.2016.08.030.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy

Szczesniak, Anna-Maria^{1,2}, Porter, Richard F.^{1,2}, Toguri, James T.¹, Borowska-Fielding, Joanna¹, Gebremeskel, Simon⁴, Siwakoti, Anuja³, Johnston, Brent⁴, Lehmann, Christian^{1,3,4,5}, Kelly, Melanie E.M.^{1,3,6}

From the Departments of Pharmacology¹, Anesthesia³, Microbiology and Immunology⁴, Physiology and Biophysics⁵, Ophthalmology and Vision Sciences⁶, Dalhousie University, Halifax, NS, Canada.

²These authors contributed equally to the work presented here and should be regarded as equivalent authors.

Supported by an operating grant to MEMK from the Canadian Institutes of Health Research (MOP-97768). Richard Porter was funded by a scholarship from the Dalhousie University Department of Ophthalmology and Visual Science: Dr. R. Evatt and Rita Mathers Graduate Scholarship.

Conflict of interest: MEM Kelly is a founding director of Panag Pharma Inc., a start-up company developing non-psychotropic cannabinoids for pain and inflammation.

Key words: Proliferative vitreoretinopathy, endocannabinoid system, cannabinoid 2 receptor, inflammation, anti-inflammatory agents

Correspondence:

Anna-Maria Szczesniak, Department of Pharmacology,
Dalhousie University,
5850 College Street,
Halifax, NS B3H 4R2,
Canada; anna.maria.szczesniak@dal.ca

Download English Version:

<https://daneshyari.com/en/article/5549038>

Download Persian Version:

<https://daneshyari.com/article/5549038>

[Daneshyari.com](https://daneshyari.com)